Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.25 Consensus Target Price from Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $6.75.

ESPR has been the topic of several recent analyst reports. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Cibc World Markets Corp bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $39,000. SJS Investment Consulting Inc. bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Versor Investments LP bought a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $44,000. Finally, SLT Holdings LLC bought a new stake in Esperion Therapeutics during the 4th quarter worth approximately $66,000. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Stock Up 5.0 %

ESPR stock opened at $1.88 on Thursday. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The firm has a market cap of $370.44 million, a P/E ratio of -2.94 and a beta of 1.01. The company’s 50-day moving average price is $2.28 and its two-hundred day moving average price is $2.12.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.